House members and patient lobbyists are concerned that CMS’ Medicaid value-based pricing proposed rule could curb drug innovation during the pandemic and make it more difficult for patients to access prescriptions. CMS proposed in June a rule that aims to avoid Medicaid “best price” pitfalls by making it easier for insurers to negotiate deals that allow drug prices to fluctuate based on how well drugs work, without forcing drug companies to sell drugs to Medicaid at very low prices. There’s...